Table 1 Clinical characteristics of the study participants.
Characteristics | Neurosyphilis at baseline (n = 123) | Neurosyphilis enrolled in follow-up (n = 58) |
|---|---|---|
Sex ratio (male: female) | 97:26 | 47:11 |
Age, median years (IQR) | 52 (46–58) | 50 (44–57) |
Baseline serum RPR titer,median (IQR) | 1:16 (1:4–1:64) | 1:32 (1:16–1:64) |
≥1:1, n (%) | 123 (100) | 58 (100) |
Baseline serum TPPA titer, median (IQR) | 1:10240 (1:2560–1:20480) | 1:10240 (1:5120–1:20480) |
≥1:80, n (%) | 123 (100) | 58 (100) |
Baseline CSF RPR titer, median (IQR) | 1:2 (negative-1:4) | 1:2 (1:1–1:4) |
≥1:1, n (%) | 86 (69.9) | 45 (77.6) |
Baseline CSF TPPA titer, median (IQR) | 1:1280 (1:320–1:10240) | 1:2560 (1:320–1:10240) |
≥1:80, n (%) | 114 (92.7) | 54 (93.1) |
Baseline CSF leukocyte count, median (IQR) | 21 (6–54) | 18 (10–56) |
>10 cells/μL, n (%) | 85 (69.7) | 43 (74.1) |
Baseline CSF protein concentration, median (IQR) | 572.1 (392.3–882.9) | 632.0 (458.0–867.0) |
>500 mg/L, n (%) | 67 (55.4) | 34 (58.6) |
Clinical stages, n (%) | ||
Asymptomatic neurosyphilis | 5 (4.1) | 4 (6.9) |
Syphilitic meningitis | 20 (16.3) | 8 (13.8) |
Meningovascular neurosyphilis | 28 (22.8) | 13 (22.4) |
General paresis | 61 (49.6) | 29 (50.0) |
Tabes dorsalis | 9 (7.3) | 4 (6.9) |
